U.S. drugmaker Pfizer Inc (PFE.N) said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus.
Data from preclinical studies of a compound that was originally developed to treat SARS – a different coronavirus that caused a major epidemic in 2003 – shows its potential to treat patients with the new coronavirus, Pfizer research chief Mikael Dolsten told Reuters in an interview.
Pfizer said it will conduct additional preclinical studies of the drug and aims to begin trials in humans in the third quarter of 2020.
